peer reviewedThere is a characteristic decrease in glucose metabolism in associative frontal and temporo-parietal cortices of patients suffering from Alzheimer's disease (AD). The decrease in metabolism might result from local neuronal loss or from a decrease of synaptic activity. We measured in vivo [11C]methionine accumulation into proteins with positron emission tomography (PET) to assess cortical tissue loss in AD. Both global regional activity and compartmental analysis were used to express [11C]methionine accumulation into brain tissue. Glucose metabolism was measures with [18F]fluorodeoxyglucose and autoradiographic method. Combined studies were performed in 10 patients with probable AD, compared to age-matched healthy volunteers. Th...
Abstract OBJECTIVE: This study tested the hypothesis that regional cerebral glucose metabolism dur...
Abstract OBJECTIVE: This study tested the hypothesis that regional cerebral glucose metabolism dur...
Using [18F] fluorodeoxyglucose (FDG) positron emission tomography (PET) patients with Alzheimer's di...
There is a characteristic decrease in glucose metabolism in associative frontal and temporo-parietal...
Reduction in the regional cerebral metabolic rate for glucose (rCMRglc) in the parietal and temporal...
Reduction in the regional cerebral metabolic rate for glucose (rCMRglc) in the parietal and temporal...
Reduction in the regional cerebral metabolic rate for glucose (rCMRglc) in the parietal and temporal...
It has been suggested that glucose metabolism within the brain's default network is directly associa...
OBJECTIVE: This study tested the hypothesis that regional cerebral glucose metabolism during neurona...
Background: Neuronal and synaptic function in Alzheimer's disease (AD) is measured in vivo by glucos...
Background: Neuronal and synaptic function in Alzheimer's disease (AD) is measured in vivo by glucos...
Objective To determine whether the hypometabolism observed in PET images of patients with Alzheimer'...
Background: Neuronal and synaptic function in Alzheimer's disease (AD) is measured in vivo by glucos...
Background: Neuronal and synaptic function in Alzheimer's disease (AD) is measured in vivo by glucos...
This study investigated cerebral glucose metabolism in very early Alzheimer's disease, before a clin...
Abstract OBJECTIVE: This study tested the hypothesis that regional cerebral glucose metabolism dur...
Abstract OBJECTIVE: This study tested the hypothesis that regional cerebral glucose metabolism dur...
Using [18F] fluorodeoxyglucose (FDG) positron emission tomography (PET) patients with Alzheimer's di...
There is a characteristic decrease in glucose metabolism in associative frontal and temporo-parietal...
Reduction in the regional cerebral metabolic rate for glucose (rCMRglc) in the parietal and temporal...
Reduction in the regional cerebral metabolic rate for glucose (rCMRglc) in the parietal and temporal...
Reduction in the regional cerebral metabolic rate for glucose (rCMRglc) in the parietal and temporal...
It has been suggested that glucose metabolism within the brain's default network is directly associa...
OBJECTIVE: This study tested the hypothesis that regional cerebral glucose metabolism during neurona...
Background: Neuronal and synaptic function in Alzheimer's disease (AD) is measured in vivo by glucos...
Background: Neuronal and synaptic function in Alzheimer's disease (AD) is measured in vivo by glucos...
Objective To determine whether the hypometabolism observed in PET images of patients with Alzheimer'...
Background: Neuronal and synaptic function in Alzheimer's disease (AD) is measured in vivo by glucos...
Background: Neuronal and synaptic function in Alzheimer's disease (AD) is measured in vivo by glucos...
This study investigated cerebral glucose metabolism in very early Alzheimer's disease, before a clin...
Abstract OBJECTIVE: This study tested the hypothesis that regional cerebral glucose metabolism dur...
Abstract OBJECTIVE: This study tested the hypothesis that regional cerebral glucose metabolism dur...
Using [18F] fluorodeoxyglucose (FDG) positron emission tomography (PET) patients with Alzheimer's di...